Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session Apr 1, 2025
Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis Jan 15, 2025
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA) May 30, 2024
Quantitative Uptake of 124I-Evuzamitide on PET Correlates with Markers of Transthyretin Cardiac Amyloidosis, Quality of Life, and Functional Status May 28, 2024
Characterizing Renal Involvement in Light Chain Amyloidosis on 124I-evuzamitide PET/MRI Imaging May 28, 2024
